RE:Is hi-liting bumbling/ fumbling....It strikes me as odd, that a Company wouldn't want to put their best foot forward when they have the kind of medical assets that they do with
little to know competitors, in a medical market with very substantial unmet needs, and with massive barriers to entry: - Why wait years before electing to trade on Nasdaq? After all, it's full of concept/zero revenue stocks that are undergoing Trials (many or most Phase 1 or 2 only, or worse not even (e.g. CTSO). Why? Presumably it's becasue it's the best place to raise capital if you are going through extended Trials.
- Why give the excuse to create a virtual posse of critics on-line and create another negative feed-back loop?
- Why such little effort in front of the Investment community vs it's many many peers in the Biotech community?
What can possibly be gained by such a strategy? Hmmmm?! That's the $ 6.4B question !
MM
SouthernTierTom wrote: A corporate strategy to enhance benefits?
I dont mean here of coarse, but as a general rule?
I never use "his" name, it is what "they" want - imho
Bon appy,
T